Phio Pharmaceuticals
PHIO
5 hedge funds and large institutions have $230K invested in Phio Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more funds holding
Funds holding: 4 → 5 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less capital invested
Capital invested by funds: $284K → $230K (-$54K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$37K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$74K |
| 2 |
Bank of New York Mellon
New York
|
-$37K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
1
Panagora Asset Management
Boston,
Massachusetts
| $50K | +$37K | +1 | New |
|
|
VKH
2
Virtu KCG Holdings
New York
| $45K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $28K | +$37K | +1 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $20K | +$37K | +1 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $19K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $15K | – | – | – |
|
7
Hudson Bay Capital Management
Stamford,
Connecticut
| $13K | – | – | – |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| $12K | -$74K | -2 | Closed |
|
9
Northern Trust
Chicago,
Illinois
| $7K | – | – | – |
|
|
10
Bank of New York Mellon
New York
| $6K | -$37K | -1 | Closed |
|
11
BlackRock
New York
| $6K | – | – | – |
|
|
RJFSA
12
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $6K | – | – | – |
|
|
FC
13
Ferris Capital
Marlborough,
Massachusetts
| $2K | – | – | – |
|
14
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
15
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14K | – | – |
|
|
16
Wells Fargo
San Francisco,
California
| – | -$3K | – | – |
|
PHIO Hedge Fund Activity: Q2 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2017, worth a combined $230K — down 19% from $284K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PHIO positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $37K. The largest seller was Vanguard Group, exiting entirely with an estimated $74K sold.
- 5 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2017, up from 4 in Q1 2017.
- Funds reported $230K of Phio Pharmaceuticals stock for Q2 2017, down 19% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q2 2017 was Citadel Advisors, an estimated $37K added.
- The largest Phio Pharmaceuticals seller in Q2 2017 was Vanguard Group, an estimated $74K sold.
Based on aggregated 13F filings for Q2 2017.